It has been shown that IL-6 (Interleukin-6), as a critical cytokine, can influence the pathogenesis of myeloma through direct activation of PI3K/AKT and MAPK pathways [29, 30]. The gene discussed is AKT1; the disease is plasma cell myeloma.